Optimal treatment strategies for unresectable stage III EGFR-mutated non-small cell lung cancer: a systematic review and Bayesian network meta-analysis - Takeaways - MDSpire

Optimal treatment strategies for unresectable stage III EGFR-mutated non-small cell lung cancer: a systematic review and Bayesian network meta-analysis

  • By

  • Yang Yang

  • Jinhan Sun

  • Ting Luo

  • Xinfu Liu

  • Yanyang Wang

  • June 26, 2026

  • 0 min

Share

  • 1

    The PACIFIC regimen is the standard care for unresectable stage III non-small cell lung cancer (NSCLC) but faces challenges in patients with EGFR mutations.

  • 2

    A total of 12 studies involving 1,529 patients were analyzed to compare six therapeutic strategies for unresectable stage III EGFR-mutated NSCLC.

  • 3

    The CRT+EGFR-TKI strategy showed a statistically significant improvement in overall survival compared to CRT alone.

  • 4

    EGFR-TKI+RT ranked first for progression-free survival and had the lowest risk of severe radiation pneumonitis.

  • 5

    The study utilized a Bayesian network meta-analysis to evaluate the efficacy and safety of various treatment strategies for unresectable stage III EGFR-mutated NSCLC.

Original Source(s)

Optimal treatment strategies for unresectable stage III EGFR-mutated non-small cell lung cancer: a systematic review and Bayesian network meta-analysis

  • by Yang Yang, Jinhan Sun, Ting Luo, Xinfu Liu, Yanyang Wang

  • June 26, 2026

Related Content

Editorial: EBV strategies to counteract the immune response

Quercetagetin-rich flavonoids from marigold induce apoptosis inhibit metastasis of non-small cell lung cancer via the p53/p21 signaling pathway

Nanomedicine delivery systems remodel the immunosuppressive microenvironment of colorectal cancer: synergistic strategies and mechanisms of targeted immune checkpoint inhibitors